Migraine Nasal Spray Market Size is valued at USD 478.79 Mn in 2022 and is predicted to reach USD 850.09 Mn by the year 2031 at a 6.8% CAGR during the forecast period for 2023-2031.
Migraine nasal sprays are used to alleviate the pain of these pounding headaches, as well as their associated nausea and hypersensitivity to light and sound. A migraine attack causes severe pain on one side of the head and additional symptoms like nausea and extreme sensitivity to light & sound. There is a varied pharmaceutical arsenal for migraine relief. Some migraine drugs are available without a doctor's prescription; others are only sold with a doctor's note. Migraine sufferers often turn to nasal sprays because they provide quicker relief than other options.
Patients with migraines report feeling better after just 15 minutes, and the comfort is greatest from the symptoms of nausea and vomiting. Market expansion is driven by fast pain relief since the medicine is taken straight into the bloodstream and not first processed by the digestive system or the liver. This implies that far more medication used to treat migraines is now readily available. As the prevalence of chronic sinusitis has grown over the years, so has the demand for nasal spray medication to alleviate the symptoms of migraines. The advancement of healthcare technology has led to an anticipated uptick in the use of nasal drugs.
However, several negative aspects seriously restrain the expansion of the migraine nasal spray market. Drug side effects include heart palpitations, shortness of breath, leg and arm muscular soreness, and moderate to severe stomach aches that can restrict migraine nasal sprays market growth. COVID-19 has also hurt the global nasal spray business. As COVID-19 symptoms spread, including high body temperature, cough, stuffy nose, and difficulty breathing, nasal sprays became necessary. During COVID-19, pharmaceutical companies increased nasal spray research and development for coronavirus treatment and prevention. The industry's adoption of telemedicine and the government's Covid-19 vaccination efforts have advanced the area.
Competitive Landscape
Some Major Key Players In The Migraine Nasal Spray Market:
- Impel NeuroPharma
- Reddy's Laboratories
- Aegis Therapeutics LLC
- Cipla
- Pfizer Inc.
- Lockhart ltd
- Tonix Pharmaceuticals
- AstraZeneca
- Upsher-Smith Laboratories
- AdvaCare Pharma
- Roche
- Sanofi
- Novartis AG
- Merck
- Baxter International Inc.
- Becton, Dickinson and Company
- GlaxoSmithKline
- Altius pharmaceuticals
Market Segmentation:
The migraine nasal spray market is segmented based on the type of chemical outlook, dosage outlook, indication outlook, and distribution channel outlook. Based on the type of chemical outlook, the market is segmented into nasal triptans, dihydroergotamine (DHE), and Non-Steroidal Anti-Inflammatory Drugs (NSAID). By dosage outlook, the market is segmented into 5 mg, 10 mg, 20 mg, and 40 mg. By indication outlook, the market is segmented into common migraines, classic migraines, cluster migraines, and others. By distribution channel outlook, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies.
Based On The Type Of Chemical, The Triptans Migraine Nasal Spray Segment Is Accounted As A Major Contributor To The Migraine Nasal Spray Market.
The triptans migraine nasal spray category is expected to record a major global market share because of the increasing prevalence of migraines and the development of effective treatments, such as the class of drugs known as triptans, which bind to serotonin-specific subtypes of receptors in the brain and cause your brain's blood vessels to contract, thereby lowering pain signals and inflammation.
The Retail Pharmacies Category Witnessed Growth At A Rapid Rate.
The retail pharmacies segment is projected to grow rapidly in the global migraine nasal spray market. Rising prevalence of chronic respiratory illnesses and nasal diseases, as these ailments increase the demand for nasal sprays to address symptoms such as a runny nose, nasal congestion, oedema, and many others. Since several nasal sprays are available without a doctor's prescription, their popularity and use have risen in retail drugstores, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Migraine Nasal Spray Market Holds A Significant Revenue Share.
The North American migraine nasal spray market activity is anticipated to record the maximum market share in revenue in the near future. It can be attributed to the rising investments in R&D for developing nasal sprays for treating various diseases and the presence of key players, which are all factors contributing to the expansion of this market. These diseases include sinusitis, allergic rhinitis, nasal polyps, the common cold, and others associated with the respiratory system.
In addition, Asia Pacific is estimated to grow rapidly in the global migraine nasal spray market because of rising healthcare costs despite advancements in headache treatment and survival rates due to the efforts of patient advocacy groups and mental health awareness campaigns. The demand for migraine nasal spray is anticipated to increase as a result of this region.
Migraine Nasal Spray Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 478.79 Mn |
|
Revenue Forecast In 2031 |
USD 850.09 Mn |
|
Growth Rate CAGR |
CAGR of 6.8% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of chemical, Dosage, Indication, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Impel NeuroPharma, Reddy's Laboratories, Aegis Therapeutics LLC, Cipla, Pfizer Inc., Lockhart Ltd, Tonix Pharmaceuticals, AstraZeneca, Upsher-Smith Laboratories, AdvaCare Pharma, Roche, Becton Dickinson and Company, Sanofi, Novartis AG, Merck, Baxter International Inc., GlaxoSmithKline, and Altius pharmaceuticals. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
